home / stock / pyxs / pyxs news


PYXS News and Press, Pyxis Oncology Inc. From 03/27/24

Stock Information

Company Name: Pyxis Oncology Inc.
Stock Symbol: PYXS
Market: NASDAQ
Website: pyxisoncology.com

Menu

PYXS PYXS Quote PYXS Short PYXS News PYXS Articles PYXS Message Board
Get PYXS Alerts

News, Short Squeeze, Breakout and More Instantly...

PYXS - Pyxis Oncology gets $8M payment for sale pf royalty rights

2024-03-27 07:43:03 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Seeking Alpha’s Quant Rating on Pyxis Oncology ...

PYXS - Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEW...

PYXS - Pyxis Oncology GAAP EPS of -$1.85 beats by $0.10

2024-03-21 11:32:38 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Read the full article on Seeking Alpha For further ...

PYXS - PHIO and MGRM among healthcare movers

2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

PYXS - BILI, EXAI and ENVB among pre-market losers

2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...

PYXS - Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWS...

PYXS - HEAR, SOUN and WW are among after hour movers

2024-03-13 17:07:28 ET Gainers: Turtle Beach ( HEAR ) +22% . SoundHound ( SOUN ) +12% . Robinhood Markets ( HOOD ) +9% . Recursion Pharmaceuticals ( RXRX ) +7% . Pyxis Oncology ( PYXS ) +3% . Losers: WW International ( ...

PYXS - Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directo...

PYXS - Learn to Evaluate (PYXS) using the Charts

2024-03-08 21:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PYXS - GENI, EA, AROC, PYXS, ASO showing five-day downward plunge

2024-03-08 09:47:01 ET Genius Sports Limited (GENI) GENI is trading DOWN for the last 4 days, and it at trading at $6.26 with volume of 1,145,622 and a one day change of $-0.03 (-0.54%). Genius Sports Limited has a 52-week low of 3.55 and a 52-week high of $8.45. The business's 50-d...

Previous 10 Next 10